In this study, AZD3965 treatment also showed to upregulate the immune checkpoint PD-L1 on NK cells, providing preliminary evidence for studying the impact of AZD3965 on anti-lymphoma immune responses and in combination with immune-modulating agents (Beloueche-Babari et al., 2020). This evidence concerns the gene CD274 and lymphoma.